Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.
Welcome to BeiMedPlus
BeiGene's medical website with resources for healthcare professionals and disease information for patients and caregivers.
Please confirm the option below that best describes you so we can direct you to appropriate resources and information.